US EditionIsomorphic Labs, Google-Backed, to Launch Human Trials for AI-Designed Drugs
- Alphabet’s drug development division, Isomorphic Labs, plans to begin clinical testing of medications created using AI technology in humans around 2025 at its London facility.
- Isomorphic Labs spun out of DeepMind in 2021 after DeepMind's AlphaFold AI predicted protein structures with high accuracy.
- The company raised $600 million in April 2025 led by Thrive Capital and signed collaborations with Novartis and Eli Lilly in 2024.
- President Colin Murdoch stated that the upcoming major objective is to begin clinical trials by testing these developments in human subjects.
- Isomorphic aims to speed up drug design, reduce costs, and improve success probabilities by combining AI with pharma expertise.
18 Articles
18 Articles
Google’s AI drug company says human trials are ‘very close’
Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. In an interview with Fortune on July 6, Colin Murdoch, Isomorphic Labs’ president and Google DeepMind’s chief business officer, shared that the company is currently gearing up to start human trials. This milestone will mark the first time that Google DeepMind’s breakthrough A…
Isomorphic Labs, Google-backed, to launch human trials for AI-designed drugs
Alphabet’s drug discovery arm, Isomorphic Labs, is preparing to enter a new chapter in its ambitious efforts to reshape medicine through artificial intelligence, with its first human clinical trials now on the horizon. Colin Murdoch, the company’s president and also Google DeepMind’s chief business officer, confirmed to Fortune that trials for AI-designed drugs could begin in the near future. “We’re staffing up now. We’re getting very close,” he…
Google DeepMind has grand ambitions to 'cure all diseases' with AI. Now, it's gearing up for its first human trials
Alphabet’s drug discovery arm is getting ready to start testing its AI-designed drugs in humans, Google DeepMind's chief business officer, told Fortune.
Isomorphic Labs Prepares To Launch Trials For AI-designed Drugs - Data Intelligence
Isomorphic Lab’s AlphaFold 3 system, developed with Google DeepMind, won its developers a Nobel Prize. Image credit: Shutterstock / Robert Way Alphabet’s AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs. In an interview with Fortune, Isomorphic Labs president Colin Murdoch shared that four years after its founding, the company is preparing to dose the first patients in clini…
Google's sister company DeepMind, Isomorphic Labs, took its first big step to apply artificial intelligence in real treatments with humans.The goal?Finding the cure for all diseases in the world.Artificial Intelligence (AI) advances by leaps and bounds, and Google, through its scientific division Isomorphic Labs, is already working on one of its most ambitious applications: curing all known diseases using AI.You may be interestedWorship Bill Gat…
Coverage Details
Bias Distribution
- 50% of the sources are Center
To view factuality data please Upgrade to Premium
